Specialty Pharmacy

By searching for hyperactive cell signals in primary effusion lymphoma, researchers were able to find a pathway that can be blocked to limit tumor growth.

Top news of the day from across the health care landscape.

The conference will take place in conjunction with the 7th National Association of Specialty Pharmacy Annual Meeting & Expo.

A regimen of afatinib as a first-line treatment followed by osimertinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer was found to significantly improve overall survival.

Identifying gene-pair relationships may help scientists understand why mutations in certain genes lead to cancer in certain tissues.

Top news of the day from across the health care landscape.

Officials with the FDA are assessing data accuracy issues related to Zolgensma, but have no major concerns about the spinal muscular atrophy treatment remaining on the market.

Effective patient-provider communication is critical to the healing process and it begins the moment the patient makes contact with the staff and continues even after the patient fills his prescription at the pharmacy.

Research could lead to the development of new cancer treatments to stop tumor growth.

Over the last 5 years, more than 4000 FDA-regulated clinical trials were initiated worldwide for rare disease treatments.

Pexidartinib (Turalio, Daiichi Sankyo) is indicated for adult patients with symptomatic tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to improvement with surgery.

Top news of the day from across the health care landscape.

The 1st annual International Congress on the Future of Neurology will be held on September 27-28, 2019 in New York City, featuring a rigorous agenda of presentations, question and answer sessions, and lightning rounds highlighting topics across the breadth of neurology.

With rapid growth, health system specialty pharmacies are more than likely to run into several operational pain points.

Top news of the week from Specialty Pharmacy Times.

Top news of the day from across the health care landscape.

Pembrolizumab (Keytruda, Merck) plus chemotherapy met the primary endpoint of pathological complete response in patients with triple-negative breast cancer in a phase 3 study.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

The findings represent the first positive phase 2b study of a personalized cancer vaccine in patients with high-risk melanoma.

With specialty pharmacy emerging as the fastest growing segment of the pharmacy industry, health systems have to address a key question: can you scale for it?

Study provides the longest available follow-up on the survival of patients with advanced melanoma, renal cell carcinoma, and non-small cell lung cancer treated with nivolumab.

Top news of the day from across the health care landscape.

Darolutamide is an androgen receptor inhibitor (ARi) for the treatment of patients with non-metastatic castration-resistant prostate cancer.

Abemaciclib (Verzenio, Eli Lilly) in combination with fulvestrant demonstrated a statistically significant improvement in overall survival among women with metastatic breast cancer previously treated with endocrine therapy.

Top news of the day from across the health care landscape.

Vaccine found to provide durable protection against the “death star” HIV strain, which is notably hard to fight.

Researchers aimed to determine the potential pathology of encephalitis as a complication of immunotherapy treatment.

Top news of the day from across the health care landscape.